Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Catalyst Pharmaceuticals (CPRX) EBIT (2016 - 2025)

Historic EBIT for Catalyst Pharmaceuticals (CPRX) over the last 16 years, with Q3 2025 value amounting to $66.3 million.

  • Catalyst Pharmaceuticals' EBIT rose 3016.76% to $66.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $258.8 million, marking a year-over-year increase of 4874.43%. This contributed to the annual value of $195.1 million for FY2024, which is 12476.62% up from last year.
  • As of Q3 2025, Catalyst Pharmaceuticals' EBIT stood at $66.3 million, which was up 3016.76% from $66.3 million recorded in Q2 2025.
  • In the past 5 years, Catalyst Pharmaceuticals' EBIT ranged from a high of $66.3 million in Q2 2025 and a low of -$37.2 million during Q3 2023
  • Moreover, its 5-year median value for EBIT was $30.8 million (2022), whereas its average is $33.3 million.
  • In the last 5 years, Catalyst Pharmaceuticals' EBIT plummeted by 24814.76% in 2023 and then surged by 23689.63% in 2024.
  • Over the past 5 years, Catalyst Pharmaceuticals' EBIT (Quarter) stood at $12.7 million in 2021, then soared by 141.73% to $30.8 million in 2022, then surged by 35.36% to $41.7 million in 2023, then surged by 50.73% to $62.8 million in 2024, then grew by 5.45% to $66.3 million in 2025.
  • Its EBIT stands at $66.3 million for Q3 2025, versus $66.3 million for Q2 2025 and $63.4 million for Q1 2025.